Study details
Enrolling now
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
Talphera, Inc
NCT IDNCT06150742ClinicalTrials.gov data as of Apr 2026
Target enrollment
70
Study length
about 1.4 years
Ages
18–80
Locations
10 sites in CA, FL, MI +6
What this study is about
Researchers are testing whether Niyad (nafamostat mesylate) is safe and effective for anticoagulation in patients undergoing continuous renal replacement therapy (CRRT). The trial will last approximately 503 days. Participants are adults who cannot tolerate heparin or have a higher risk of bleeding.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Use Niyad (nafamostat mesylate)
- 2.Use Placebo (0.9% NaCl)
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Renal